The European Strategic Cluster Partnership alliance on Personalised Healthcare, bioXclusters plus, which joins together four leading European Bio Clusters – Biocat, BioM, BioPmed and Lyonbiopole – is pleased to invite European SMEs based in its regions to join its mission to Japan. This mission has been organised in the framework of BioJapan (Oct. 12 to 14, 2016). Continue reading
The European meta-cluster project bioXclusters plus (European Strategic Cluster Partnership on Personalised Healthcare) has been selected by the European Commission Executive Agency for Small and Medium-sized Entreprises (EASME) for the call for proposals COS-CLUSTER-2014-3-03 – Cluster Going International. Continue reading
The “EU‐Japan Cluster Matchmaking Event” was held at BIO‐Europe in Frankfurt, Germany, on 3rd November, 2014. Leading Japanese health care cluster representatives and their European counterparts met at this event to begin to build bridges between their organisations and to path the way for potential collaborations –as part of their goal to help SMEs find business partners. Continue reading
The EU‐Japan Cluster Matchmaking Event – financially supported by the European Commission (http://www.clustercollaboration.eu) – is taking place at Bio Europe in Frankfurt (Germany) on November, 3rd. This event will provide the perfect opportunity for attendees to gain an overview of the strengths of Japanese life sciences and its clusters in the healthcare sector. Continue reading
The bioXclusters partners, along with some European SMEs, visited Boston (Massachusetts) in October 2013. Read this interesting report that includes the description of the visit and information about the life sciences market in this country.
The bioXclusters partners are now back from their US Mission and would like to thank everyone who helped make their trip so successful and who, in addition, helped them gain a much greater understanding of the opportunities which this market represents and the life sciences environment in the US in general.
Internationalisation, especially in China, is considered sometimes to be something of an issue by SMEs and clusters. In life sciences, it is not an option. This sector’s activity cannot be restricted to national borders. Continue reading